Holen Sie sich die Stockscreener-App
86.00
1.89%
-1.66
Handel nachbörslich:
86.09
0.09
+0.10%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt EW?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$87.66
Offen:
$87.63
24-Stunden-Volumen:
4.96M
Relative Volume:
0.98
Marktkapitalisierung:
$49.52B
Einnahmen:
$6.30B
Nettoeinkommen (Verlust:
$1.07B
KGV:
46.72
EPS:
1.8406
Netto-Cashflow:
$1.09B
1W Leistung:
-0.59%
1M Leistung:
+2.41%
6M Leistung:
+2.41%
1J Leistung:
+10.65%
1-Tages-Spanne:
$85.81
$87.90
1-Wochen-Bereich:
$85.81
$89.14
52-Wochen-Spanne:
$72.30
$89.14
Edwards Lifesciences Corp Stock (EW) Company Profile
Firmenname
Edwards Lifesciences Corp
Sektor
Branche
Telefon
(949) 250-2500
Adresse
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
86.00 | 50.47B | 6.30B | 1.07B | 1.09B | 1.8406 |
ABT
Abbott Laboratories
|
86.99 | 151.49B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
295.00 | 112.44B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
77.95 | 94.69B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
47.69 | 70.87B | 20.62B | 3.56B | 3.48B | 2.3847 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-01 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2026-01-09 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-12-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | Hochstufung | Jefferies | Hold → Buy |
| 2025-10-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-04-24 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Hochstufung | Stifel | Hold → Buy |
| 2025-01-16 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-31 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-25 | Herabstufung | Truist | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-02-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-28 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-03-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Herabstufung | Bernstein | Outperform → Underperform |
| 2023-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Herabstufung | Stifel | Buy → Hold |
| 2022-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Eingeleitet | Mizuho | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-29 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Eingeleitet | Truist | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-03-16 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-27 | Bestätigt | Citigroup | Buy |
| 2022-01-27 | Bestätigt | Evercore ISI | Outperform |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Buy |
| 2022-01-27 | Bestätigt | UBS | Neutral |
| 2021-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-30 | Bestätigt | Deutsche Bank | Hold |
| 2021-07-30 | Bestätigt | Jefferies | Buy |
| 2021-07-30 | Bestätigt | Morgan Stanley | Overweight |
| 2021-07-30 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-30 | Bestätigt | Stifel | Buy |
| 2021-07-30 | Bestätigt | UBS | Neutral |
| 2021-07-30 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-04-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-11 | Bestätigt | Canaccord Genuity | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Underperform |
| 2020-04-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Bestätigt | Canaccord Genuity | Buy |
| 2019-09-23 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-24 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-18 | Bestätigt | Canaccord Genuity | Buy |
| 2019-01-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Hold |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-10-02 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Herabstufung | Guggenheim | Buy → Neutral |
Alle ansehen
Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten
Bank of New York Mellon Corp Sells 1,517,638 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
TD Cowen raises Edwards Lifesciences stock price target on TAVR market share gains - Investing.com
Nomura Asset Management Co. Ltd. Has $36.83 Million Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corp. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Edwards Lifesciences (EW) CFO Theodora Mistras files initial Form 3 report - Stock Titan
Intech Investment Management LLC Has $5.91 Million Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Insider Sell: Andrew Dahl Sells Shares of Edwards Lifesciences C - GuruFocus
Geode Capital Management LLC Trims Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Andrew Dahl Sells 568 Shares of Edwards Lifesciences (NYSE:EW) Stock - MarketBeat
Edwards Lifesciences (EW) SVP records small open-market stock sale - Stock Titan
Edwards Lifesciences (NYSE: EW) affiliate reports two 13,000-share sales - Stock Titan
Edwards Lifesciences (NYSE: EW) files Form 144 for proposed common sale - Stock Titan
Boston Scientific’s $1.5B bet signals heart valve market battle - Modern Healthcare
EW News | EDWARDS LIFESCIENCES CORP (NYSE:EW) - ChartMill
Edwards Lifesciences Corp. Hits New 52-Week High at USD 88.25 - Markets Mojo
Edwards Lifesciences Corp. Hits New 52-Week High at USD 87.93 - Markets Mojo
Allstate Corp Grows Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Is Edwards Lifesciences (EW) Fairly Priced After Recent Share Price Strength? - Yahoo Finance
Edwards Lifesciences CVP Donald Bobo Jr. sells $2m in stock - Investing.com UK
Edwards Lifesciences CVP Donald Bobo Jr. sells $2m in stock By Investing.com - Investing.com Australia
Edwards Lifesciences (EW) executive sells 23,145 shares at $86.42 average price - Stock Titan
Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Donald Bobo reports multiple Common stock sales (EW) in Form 144 - Stock Titan
Edwards Lifesciences Has Everything Investors Want Except Value (NYSE:EW) - Seeking Alpha
Legal & General Group Plc Has $376.46 Million Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences stock hits 52-week high at 87.89 USD - Investing.com
Edwards Lifesciences stock hits 52-week high at 87.89 USD By Investing.com - Investing.com UK
Swedbank AB Lowers Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences’ SWOT analysis: stock gains from rival’s setback By Investing.com - Investing.com Australia
Edwards Lifesciences’ SWOT analysis: stock gains from rival’s setback - Investing.com
Edwards Lifesciences Corp. (EW) Stock Analysis: Healthcare Giant with 13% Upside Potential - DirectorsTalk Interviews
Edwards Lifesciences Corporation (NYSE:EW) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Edwards Lifesciences Corporation $EW Shares Sold by Rathbones Group PLC - MarketBeat
ABN Amro Investment Solutions Raises Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
EW Price History for Edwards Lifesciences Corp Stock - Barchart.com
Insider Sell Alert: Daveen Chopra Sells Shares of Edwards Lifesc - GuruFocus
Analysts Offer Insights on Healthcare Companies: P3 Health Partners (PIII) and Edwards Lifesciences (EW) - The Globe and Mail
Edwards Lifesciences Corp (EW) Stock Up 3.1% and Still Undervalued -- GF Score: 95/100 - GuruFocus
Edwards Lifesciences (NYSE: EW) exec sells 1,500 common shares - Stock Titan
Edwards Lifesciences (EW) Form 144: Broker-listed proposed sale notice - Stock Titan
19,073 Shares in Edwards Lifesciences Corporation $EW Purchased by Fideuram Intesa Sanpaolo Private Banking S.P.A. - MarketBeat
Investment House LLC Trims Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
North Dakota State Investment Board Buys Shares of 19,728 Edwards Lifesciences Corporation $EW - MarketBeat
Handelsbanken Fonder AB Has $102.60 Million Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences CVP Lippis sells $50,306 of common stock By Investing.com - Investing.com Nigeria
Insider Sell Alert: Daniel Lippis Sells Shares of Edwards Lifesc - GuruFocus
Edwards Lifesciences (NYSE:EW) VP Sells $50,306.80 in Stock - MarketBeat
Edwards Lifesciences CVP Lippis sells $50,306 of common stock - Investing.com
Edwards Lifesciences CVP, Strategy/Corp Development Sold Shares Worth Over $1.4M - TradingView
Edwards Lifesciences exec sells 620 shares after option exercise | EW Insider Trading - Stock Titan
Finanzdaten der Edwards Lifesciences Corp-Aktie (EW)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.06%
0.93%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):